| 000 | 00815 a2200241 4500 | ||
|---|---|---|---|
| 005 | 20250517215811.0 | ||
| 264 | 0 | _c20180525 | |
| 008 | 201805s 0 0 eng d | ||
| 022 | _a1533-4406 | ||
| 024 | 7 |
_a10.1056/NEJMc1802999 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBhatt, Jay | |
| 245 | 0 | 0 |
_aConsequences of the 340B Drug Pricing Program. _h[electronic resource] |
| 260 |
_bThe New England journal of medicine _c05 2018 |
||
| 300 |
_a2053 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 | _aCosts and Cost Analysis |
| 650 | 0 | 4 | _aDrug Costs |
| 650 | 0 | 4 | _aHumans |
| 700 | 1 | _aOrlowski, Janis M | |
| 773 | 0 |
_tThe New England journal of medicine _gvol. 378 _gno. 21 _gp. 2053 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1056/NEJMc1802999 _zAvailable from publisher's website |
| 999 |
_c28421654 _d28421654 |
||